



Imugene SPP Results & \$181K R&D Refund

Melbourne, 4 June 2013: Imugene Limited ('Company') is pleased to announce that the Company has successfully closed its Share Purchase Plan ('SPP') announced on 30 April 2013. Imugene has received SPP applications for 33,888,932 new fully paid ordinary shares in the Company ('New Shares') raising \$183,000. New Shares will be issued at \$0.0054 per share, the issue price being a 10% discount to the volume weighted average price of Imugene shares as traded on ASX over the 10 trading days prior to 4 June 2013. No applications under the SPP were scaled back.

Net proceeds raised from the SPP will be used for working capital purposes and to advance Imugene's lead products to regulatory filing in the United Kingdom and European Union.

The Board of Imugene takes this opportunity to thank all shareholders who participated in the SPP for their continued support of the Company.

Remaining dates for the SPP are as follows:

Allotment and Issue of Shares under the SPP.	Tuesday, 4 June 2013
Application to ASX for official quotation of Shares issued under the SPP.	Tuesday, 4 June 2013
Dispatch Date.	Thursday, 6 June 2013

In addition to the funds raised under the SPP, the Company has also received a cash refund of \$181,354 under the R&D Tax Incentive Program, a program administered by AusIndustry and the Australian Taxation Office.

Dr Nick Ede, Executive Director commented "The receipt of funds from the SPP and the R&D Tax Incentive Program is a very important component of the funding required to take our programs through to commercialisation. As a Company with a drug delivery platform technology involving a number of clinical and development programs, the R&D Tax Incentive from the Government is of great assistance."

- Ends -

For investor enquiries please contact:

Dr Nick Ede, Imugene – 0400 642 254 / nede@imugene.com

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.

For personal use only